{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:38:14Z","timestamp":1791999494612,"version":"4.4.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Endo Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The efficacy and safety of collagenase Clostridium histolyticum (CCH) have been demonstrated in the treatment of men with Peyronie\u2019s disease (PD); however, the pivotal clinical trials excluded men with ventral penile curvature.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>The study sought to evaluate outcomes of CCH treatment in men with ventral curvatures secondary to PD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Men with PD treated with CCH were identified from a prospective database. Patients received up to 4 series of CCH injections using a progressively modified protocol over time. Results were compared between those with baseline ventral vs nonventral penile curvatures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>Changes in penile curvature, Peyronie\u2019s Disease Questionnaire scores, International Index of Erectile Function scores, nonstandardized assessments, and adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 560 men with PD (85 ventral curvature, 475 nonventral curvature) were included in the analysis. Baseline median curvature was 60.0\u00b0 (interquartile range, 48.8\u00b0-75.0\u00b0) in the ventral cohort and 65.0\u00b0 (interquartile range, 45.0\u00b0-80.0\u00b0) in the nonventral cohort. Median change from baseline penile curvature was \u221225.0\u00b0 in the ventral cohort vs \u221224.0\u00b0 in the nonventral cohort (P = .08, between-group comparison), which corresponded to curvature reductions of 44.7% and 33.6%, respectively (P = .03). In the subset of patients who completed CCH treatment (ie, received 8 injections or discontinued early because of patient satisfaction with curvature reduction), median change from baseline was \u221235.0\u00b0 in the ventral cohort vs \u221225.0\u00b0 in the nonventral cohort (P &amp;lt; .05); median percent improvement was 48.3% and 37.5%, respectively (P\u2009=\u2009.11). Median change from baseline in Peyronie\u2019s Disease Questionnaire and International Index of Erectile Function domain scores and adverse events were similar between cohorts, with the exception of possibly higher hematoma rates in the nonventral group (50% vs 37%; P\u2009=\u2009.05). No urethral injuries were sustained in either cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>Data support the use of CCH for the treatment of ventral as well as nonventral penile curvatures in men with PD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>Study strengths are the inclusion of a general clinical population of men with PD, the prospective design, and the relatively large series of men with ventral curvature. Limitations include the single-center and observational nature of the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>CCH was safe and effective in the treatment of both ventral and nonventral penile curvatures in men with PD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdad167","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T15:52:40Z","timestamp":1703346760000},"page":"169-174","source":"Crossref","is-referenced-by-count":5,"title":["Outcomes of collagenase <i>Clostridium histolyticum<\/i> in men with ventral curvatures: an updated series"],"prefix":"10.1093","volume":"21","author":[{"given":"Henry","family":"Larson","sequence":"first","affiliation":[{"name":"Brigham Young University, Department of Physiology and Developmental Biology , Provo, UT 84602, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Savage","sequence":"additional","affiliation":[{"name":"Male Fertility and Peyronie\u2019s Clinic , Orem, UT 84057, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klint","family":"Brearton","sequence":"additional","affiliation":[{"name":"Male Fertility and Peyronie\u2019s Clinic , Orem, UT 84057, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley","family":"Warner","sequence":"additional","affiliation":[{"name":"Male Fertility and Peyronie\u2019s Clinic , Orem, UT 84057, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ziegelmann","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Department of Urology , Rochester, MN 55905, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Kohler","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Department of Urology , Rochester, MN 55905, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landon","family":"Trost","sequence":"additional","affiliation":[{"name":"Brigham Young University, Department of Physiology and Developmental Biology , Provo, UT 84602, United States"},{"name":"Male Fertility and Peyronie\u2019s Clinic , Orem, UT 84057, United States"},{"name":"Mayo Clinic, Department of Urology , Rochester, MN 55905, United States"},{"name":"CURE PD , Orem, UT 84057, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"issue":"4","key":"2024020509071002800_ref1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0022-5347(17)37988-0","article-title":"The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984","volume":"146","author":"Lindsay","year":"1991","journal-title":"J Urol"},{"key":"2024020509071002800_ref2","doi-asserted-by":"crossref","first-page":"282503","DOI":"10.1155\/2011\/282503","article-title":"A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States","volume":"2011","author":"Dibenedetti","year":"2011","journal-title":"Adv Urol"},{"issue":"7","key":"2024020509071002800_ref3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1464-4096.2001.02436.x","article-title":"The prevalence of Peyronie's disease: results of a large survey","volume":"88","author":"Schwarzer","year":"2001","journal-title":"BJU Int"},{"issue":"5","key":"2024020509071002800_ref4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.ijir.3900727","article-title":"Prevalence of Peyronie's disease in men over 50-y-old from southern Brazil","volume":"13","author":"Rhoden","year":"2001","journal-title":"Int J Impot Res"},{"issue":"5","key":"2024020509071002800_ref5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1159\/000049830","article-title":"Peyronie's disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years","volume":"40","author":"La Pera","year":"2001","journal-title":"Eur Urol"},{"issue":"6 Part 1","key":"2024020509071002800_ref6","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1097\/01.ju.0000127744.18878.f1","article-title":"Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening","volume":"171","author":"Mulhall","year":"2004","journal-title":"J Urol"},{"issue":"6","key":"2024020509071002800_ref7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/sj.ijir.3901247","article-title":"Incidentally diagnosed Peyronie's disease in men presenting with erectile dysfunction","volume":"16","author":"Kadioglu","year":"2004","journal-title":"Int J Impot Res"},{"issue":"3","key":"2024020509071002800_ref8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.eururo.2005.10.026","article-title":"Prevalence of Peyronie's disease among patients with erectile dysfunction","volume":"49","author":"El-Sakka","year":"2006","journal-title":"Eur Urol"},{"issue":"2","key":"2024020509071002800_ref9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ijir.3901518","article-title":"The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction","volume":"19","author":"Arafa","year":"2007","journal-title":"Int J Impot Res"},{"issue":"3","key":"2024020509071002800_ref10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0022-5347(05)64578-8","article-title":"A retrospective review of 307 men with Peyronie's disease","volume":"168","author":"Kadioglu","year":"2002","journal-title":"J Urol"},{"issue":"6","key":"2024020509071002800_ref11","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","article-title":"An analysis of the natural history of Peyronie's disease","volume":"175","author":"Mulhall","year":"2006","journal-title":"J Urol"},{"issue":"3","key":"2024020509071002800_ref12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4321\/S0004-06142007000300021","article-title":"The natural history of Peyronie's disease","volume":"60","author":"Grasso","year":"2007","journal-title":"Arch Esp Urol"},{"issue":"1","key":"2024020509071002800_ref13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"key":"2024020509071002800_ref14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.urology.2019.01.055","article-title":"Safety and efficacy of collagenase Clostridium histolyticum in Peyronie's disease men with ventral curvatures","volume":"129","author":"Alom","year":"2019","journal-title":"Urology"},{"key":"2024020509071002800_ref15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.urology.2022.09.017","article-title":"Improved Peyronie's disease curvature outcomes using a novel collagenase administration protocol","volume":"170","author":"Flores","year":"2022","journal-title":"Urology"},{"key":"2024020509071002800_ref16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.urology.2018.06.003","article-title":"Plaque calcification: an important predictor of collagenase clostridium Histolyticum treatment outcomes for men with Peyronie's disease","volume":"119","author":"Wymer","year":"2018","journal-title":"Urology"},{"issue":"6","key":"2024020509071002800_ref17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jsxm.2019.03.007","article-title":"Efficacy of combined collagenase clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie's disease","volume":"16","author":"Alom","year":"2019","journal-title":"J Sex Med"},{"issue":"6","key":"2024020509071002800_ref18","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.juro.2015.06.096","article-title":"Intralesional injection of interferon-\u03b12b improves penile curvature in men with Peyronie's disease independent of plaque location","volume":"194","author":"Stewart","year":"2015","journal-title":"J Urol"},{"issue":"4","key":"2024020509071002800_ref19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/andr.12368","article-title":"Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study","volume":"5","author":"Favilla","year":"2017","journal-title":"Andrology"},{"key":"2024020509071002800_ref20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.urology.2017.01.054","article-title":"Clinical experience with penile traction therapy among men undergoing collagenase clostridium histolyticum for Peyronie disease","volume":"104","author":"Ziegelmann","year":"2017","journal-title":"Urology"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/21\/2\/169\/56549853\/qdad167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/21\/2\/169\/56549853\/qdad167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T09:07:28Z","timestamp":1707124048000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/21\/2\/169\/7491971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,12,22]]},"published-print":{"date-parts":[[2024,1,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdad167","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,12,22]]}}}